Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
Gilead will present 28 abstracts, including two oral presentations, across HIV treatment, prevention, and emerging antiviral research at IDWeek 2026, October 21-24 in Washington, D.C. Key highlights include new Phase 3 ARTISTRY-1 and ARTISTRY-2 analyses of Bixlenvo in patients with comorbidities or renal impairment, real-world evidence on early U.S. adoption of twice-yearly Yeztugo for PrEP, and final Phase 1b results for the investigational HSV asset GS-1179.
Key figures
- Oral presentations
- 2
- Presentation count
- 28
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.